NCT07343037

Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care: Relevance of the Hscore and Search for the Best Diagnostic Markers

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings. In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction. The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.

Conditions

• Hepatic Insufficiency
• Cirrhosis, Liver

Timeline

• Start date: 2025-08-29
• Primary completion: 2026-08-01
• Completion: 2026-08-29
• First posted: 2026-01-15
• Last updated: 2026-01-15

Locations

1 site across 1 country: France